F
Feng Wang
Researcher at Nantong University
Publications - 37
Citations - 678
Feng Wang is an academic researcher from Nantong University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 11, co-authored 28 publications receiving 461 citations.
Papers
More filters
Journal ArticleDOI
Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer
Chunjing Jin,Wei Shi,Feng Wang,Xianjuan Shen,Jing Qi,Hui Cong,Jie Yuan,Linying Shi,Bingying Zhu,Xi Luo,Yan Zhang,Shaoqing Ju +11 more
TL;DR: Ju et al. as mentioned in this paper found that a high serum HULC level correlated with tumor size, lymph node metastasis, distant metastases, tumor-node-metastasis stage, and H. pylori infection.
Journal ArticleDOI
Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma.
TL;DR: It is indicated that serum miR-182 andmiR-331-3p, upregulated in HCC, can provide positive diagnostic and prognostic values for HCC.
Journal ArticleDOI
LncRNAs and their role in cancer stem cells.
TL;DR: The progress of lNCRNAs and cancer stem cells are reviewed and the potential signal pathways of lncRNAs in cancer stemness are discussed.
Journal ArticleDOI
Down‐regulated lncRNA SLC25A5‐AS1 facilitates cell growth and inhibits apoptosis via miR‐19a‐3p/PTEN/PI3K/AKT signalling pathway in gastric cancer
TL;DR: This study indicated that SLC25A5‐AS1 was down‐regulated in GC and functioned as a suppressor in the progression of GC, and could act as a ceRNA to regulate cellular behaviours via miR‐19a‐3p/PTEN/PI3K/AKT signalling pathway.
Journal ArticleDOI
miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL
TL;DR: The present study provided the first evidence that miR-383 was decreased in HCC and associated with tumor progression and prognosis of HCC patients and confirmed that mi R-383 might inhibit HCC cell proliferation partially via downregulating APRIL expression.